Monrovia, California (PressExposure) June 29, 2011 -- Kanta Subbarao, Chief of Emerging Respiratory Viruses Section at the National Institute of Allergy and Infectious Diseases, National Institute of Health, to deliver keynote presentation at the "9th Annual Vaccines Discovery and Development: All Things Considered" conference, to be held on Nov. 7-8, 2011 in Boston, MA by GTC.
Dr. Kanta Subbarao will discuss the development of novel prophylactic and therapeutic interventions to prevent the spread of a pandemic. The novel H1N1 virus that emerged in 2009 rapidly spread around the world and caused the first influenza pandemic in 40 years. Highly pathogenic avian influenza A H5N1 viruses have been circulating in avian species since 1997 and have caused more than 500 human infections and more than 300 deaths since 2003. Vaccination is the key strategy to prevent severe illness and death from pandemic influenza. Active and passive immunization approaches are useful for prophylaxis and/or adjunctive treatment of human infections by novel influenza viruses.
Dr. Kanta Subbarao is a specialist in pediatric infectious diseases. She was Chief of the Molecular Genetics Section of the Influenza Branch at the CDC before she joined the NIH, where she is Chief of the Emerging Respiratory Viruses Section of the Laboratory of Infectious Diseases, NIAID. Dr. Subbarao's research is focused on newly emerging viral diseases of global importance: pandemic influenza and the severe acute respiratory syndrome (SARS). The goal of Dr. Subbarao's influenza program is to generate and evaluate vaccines against potential pandemic strains of influenza.
The 9th Vaccine Discovery and Development: All Things Considered conference annually brings together experts in vaccines from big and small pharmaceutical companies, academia, and government. The intimate setting of the conference enables networking and the opportunity to meet speakers and delegates. This year's conference will appropriately take place in Boston, MA, the hub of research and development.
The purpose of the event is to generate dialogue and to introduce novel advances in the field of vaccines. It is part of a two-track meeting that will take place at the Omni Parker House. Delegates at this event will have a chance to meet the attendees of the concurrent 8th Anti-Infectives Partnering and Deal-Making conference.
The sessions for this conference are:
Vaccines for Infectious Diseases
Regulatory and Government Policy
New Technologies in Vaccine Development
Future Trends in Vaccine Discovery and New Vaccines
For more information, please visit http://www.gtcbio.com.